MX2014004492A - Composicion farmaceutica sinergistica de dos analgesicos con distinto perfil farmacocinetico. - Google Patents

Composicion farmaceutica sinergistica de dos analgesicos con distinto perfil farmacocinetico.

Info

Publication number
MX2014004492A
MX2014004492A MX2014004492A MX2014004492A MX2014004492A MX 2014004492 A MX2014004492 A MX 2014004492A MX 2014004492 A MX2014004492 A MX 2014004492A MX 2014004492 A MX2014004492 A MX 2014004492A MX 2014004492 A MX2014004492 A MX 2014004492A
Authority
MX
Mexico
Prior art keywords
effects
drugs
drug
analgesics
analgesic
Prior art date
Application number
MX2014004492A
Other languages
English (en)
Other versions
MX351622B (es
Inventor
Graciela De Los Ángeles Aguilera Suárez
Martha Rosaura Juárez Lora
Carmen Miguel Gómez Sánchez
Original Assignee
Farmacéuticos Rayere S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51989148&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2014004492(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Farmacéuticos Rayere S A filed Critical Farmacéuticos Rayere S A
Publication of MX2014004492A publication Critical patent/MX2014004492A/es
Publication of MX351622B publication Critical patent/MX351622B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a composiciones farmacéuticas que contienen dos principios activos siendo uno de ellos un analgésico antiinflamatorio no esteroideo conocido como meloxicam o una de sus sales farmacéuticamente aceptables y el otro un analgésico antiinflamatorio no esteroideo conocido como clonixinato de usina. Cuando se combinan ambos fármacos en proporciones específicas, la combinación produce efectos farmacológicos de analgesia que indican una súper-aditividad (sinergia) así como una potenciación del efecto antiinflamatorio, por lo que es posible usar menos cantidad de ambos fármacos para lograr los mismos efectos terapéuticos que cuando se usan solos. Al disminuir la cantidad de cada fármaco en la combinación, los efectos colaterales asociados con cada uno de ellos se reducen en número y en grado, por lo tanto esta estrategia terapéutica puede ser una herramienta promisoria en el alivio del dolor agudo moderado a severo con la ventaja de tener menos efectos adversos.
MX2014004492A 2013-05-27 2013-05-27 Composicion farmaceutica sinergistica de dos analgesicos con distinto perfil farmacocinetico. MX351622B (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2013/000070 WO2014193210A1 (es) 2013-05-27 2013-05-27 Composición farmacéutica sinergística de dos analgésicos con distinto perfil farmacocinético

Publications (2)

Publication Number Publication Date
MX2014004492A true MX2014004492A (es) 2016-03-15
MX351622B MX351622B (es) 2017-10-17

Family

ID=51989148

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014004492A MX351622B (es) 2013-05-27 2013-05-27 Composicion farmaceutica sinergistica de dos analgesicos con distinto perfil farmacocinetico.

Country Status (6)

Country Link
EP (1) EP3025717B1 (es)
BR (1) BR112015024314A2 (es)
CR (1) CR20150666A (es)
ES (1) ES2586607B1 (es)
MX (1) MX351622B (es)
WO (1) WO2014193210A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2262967B1 (es) * 1974-03-07 1977-11-04 Roemmers Sa Ind Comercial
DE4037554A1 (de) * 1990-11-26 1992-05-27 Roemmers Sa Arzneimittel zur topischen anwendung
US8512727B2 (en) * 2003-03-03 2013-08-20 Alkermes Pharma Ireland Limited Nanoparticulate meloxicam formulations
WO2007083985A1 (es) * 2006-01-19 2007-07-26 Farmacéuticos Rayere, S.A. Composición farmacéutica sinergística de diclofenaco y clonixinato de lisina
US20070281927A1 (en) * 2006-06-06 2007-12-06 Shanthakumar Tyavanagimatt Anti-inflammatory and analgesic compositions and related methods
WO2007148950A1 (es) * 2006-06-20 2007-12-27 Farmacéuticos Rayere, S.A. Composición farmacéutica sinergística de ketorolaco y clonixinato de lisina
MX357376B (es) * 2011-06-22 2018-07-06 Laboratorios Senosiain S A De C V Star Composicion farmaceutica para uso en inflamacion y dolor.

Also Published As

Publication number Publication date
ES2586607B1 (es) 2017-07-20
EP3025717B1 (en) 2018-11-07
EP3025717A4 (en) 2017-03-15
EP3025717A1 (en) 2016-06-01
WO2014193210A1 (es) 2014-12-04
CR20150666A (es) 2016-03-03
ES2586607A1 (es) 2016-10-17
BR112015024314A2 (pt) 2017-07-18
MX351622B (es) 2017-10-17

Similar Documents

Publication Publication Date Title
HRP20200600T1 (hr) Tapentadol za sprječavanje i liječenje depresije i tjeskobe
BR112015027297A8 (pt) administração local e concomitante de nanocarreadores sintéticos tolerogênicos para reduzir hipersensibilidade dos tipos i e iv
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
WO2013158680A3 (en) Compositions and methods comprising celecoxib or related compounds and dextromethorphan
MX2021000376A (es) Composiciones tópicas para el alivio del dolor.
NZ714963A (en) Compositions and methods for treating anemia
EA201491285A1 (ru) Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
FI3562486T3 (fi) Kielenalaisen deksmedetomidiinin käyttö agitaation hoidossa
WO2009051840A3 (en) Compositions and methods for reducing hepatotoxicity associated with drug administration
BR112018012870A2 (pt) métodos e composições para o tratamento de transtornos relacionados à crise
EA201690679A1 (ru) Стабильная фармацевтическая композиция, содержащая амлодипин и валсартан
MX2018000084A (es) Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina.
JP2014504636A5 (es)
MX363389B (es) Composicion farmaceutica que comprende ivabradina amorfa.
WO2014071168A3 (en) Administering inhibitors of tgfbeta signaling to improve muscle function in cancer patients
PH12018500817A1 (en) Pharmaceutical composition comprising metformin and lobeglitazone
MY180772A (en) Novel therapeutic mirtazapine combinations for use in pain disorders
GR1008228B (el) Φαρμακευτικο σκευασμα περιεχον ενα διπλο αναστολεα επαναπροσληψης και μεθοδος για την παρασκευη αυτου
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
MX348595B (es) Composicion farmaceutica con agentes antiinflamatorios y proceso de produccion.
MX351622B (es) Composicion farmaceutica sinergistica de dos analgesicos con distinto perfil farmacocinetico.
MX2018003890A (es) Composiciones farmaceuticas que contienen un relajante muscular y un antiinflamatorio no esteroideo (aine).
PE20160038A1 (es) Composicion farmaceutica sinergistica de dos analgesicos con distinto perfil farmacocinetico
WO2020036478A3 (es) Composición farmacéutica sinérgica de aceclofenaco y betametasona para el tratamiento del dolor en las formas localizadas de afecciones reumáticas
MX2018015759A (es) Regimenes de dosificacion de vortioxetina para el rapido inicio del efecto antidepresivo.

Legal Events

Date Code Title Description
FG Grant or registration